Recommendation ID
CG182/3
Question
For people aged over 75 years with CKD, what is the clinical effectiveness of renin–angiotensin–aldosterone system (RAAS) antagonists?
Any explanatory notes
(if applicable)
Why this is important: RAAS antagonists are among the most commonly used drugs. They are recommended for people with CKD to reduce the rate of disease progression and mortality. The evidence for the use of RAAS antagonists is not specific to older people, so these recommendations are the same for all adults, regardless of age. However, there is a clinical suspicion that older people have a higher incidence of adverse effects from using RAAS antagonists, and uncertainty as to the balance of benefits and harm of using these agents in older people.

Source guidance details

Comes from guidance
Chronic kidney disease in adults: assessment and management
Number
CG182
Date issued
July 2014

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 07/10/2014